title: Risk factors contributing to urinary protein expression resulting from bevacizumab combination chemotherapy.
abstract: Proteinuria following administration of bevacizumab is reported to be a specific adverse effect, but the risk factors for proteinuria have not been elucidated. In this study, the risk factors for urinary protein expression resulting from bevacizumab combination chemotherapy were investigated. The subjects were 47 patients aged > or = 20 years who had received bevacizumab combination chemotherapy at Gifu Municipal Hospital between February 2010 and February 2011. A total of 13 patients were excluded based on exclusion criteria; of the remaining 34 patients, 24 (70.6%) were assigned to the urinary protein non-expression group, and 10 (29.4%) were assigned to the urinary protein expression group. The results of multivariate logistic regression analysis revealed a significant difference in systolic blood pressure (> or =130 mmHg) between the two groups (OR: 14.499, 95%CI: 1.326-158.577, p=0.028). This finding shows that systolic blood pressure (> or =130 mmHg) is a risk factor for urinary protein expression resulting from bevacizumab combination chemotherapy.
authors.affiliation: Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu, Japan. teramachih@gifu-pu.ac.jp
authors.forename: H
authors.initials: H
authors.lastname: Teramachi
authors.forename: H
authors.initials: H
authors.lastname: Shiga
authors.forename: N
authors.initials: N
authors.lastname: Komada
authors.forename: K
authors.initials: K
authors.lastname: Tamura
authors.forename: M
authors.initials: M
authors.lastname: Yasuda
authors.forename: M
authors.initials: M
authors.lastname: Umeda
authors.forename: T
authors.initials: T
authors.lastname: Tachi
authors.forename: C
authors.initials: C
authors.lastname: Goto
authors.forename: T
authors.initials: T
authors.lastname: Tsuchiya
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D000068258:Bevacizumab; D001774:Blood Chemical Analysis; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D011507:Proteinuria / Q000139:chemically induced* / Q000378:metabolism; D012189:Retrospective Studies; D012307:Risk Factors
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab